Last updated: September 27, 2025
Introduction
Mexico Patent MX395463, titled “Method for manufacturing a pharmaceutical composition for treating neurological disorders,” was granted by the Mexican Institute of Industrial Property (IMPI) on August 18, 2022. As part of the strategic landscape for pharmaceutical innovation and intellectual property management, understanding the scope, claims, and patent landscape surrounding MX395463 is critical for stakeholders including pharmaceutical companies, generic manufacturers, research firms, and legal entities.
This analysis provides a comprehensive examination of the patent’s scope, its claimed innovations, and its position within the broader patent environment concerning neurological disorder therapeutics in Mexico and globally.
Scope and Claims of MX395463
1. Patent Abstract and Core Subject Matter
The patent claims a specific method for preparing a pharmaceutical composition aimed at treating neurological conditions such as Parkinson’s disease, Alzheimer’s disease, or other neurodegenerative disorders. At its core, the invention relates to a formulation comprising a novel combination of active ingredients and a specific manufacturing process that enhances bioavailability and reduces adverse effects.
2. Key Claims Overview
The primary claims are focused on:
-
Method of Preparation:
The patent claims a novel process involving specific steps of combining active pharmaceutical ingredients (APIs) with excipients under controlled conditions, notably through a particular sequence of granulation, drying, and encapsulation steps. This process purportedly results in a stable, high-penetration formulation.
-
Pharmacologically Active Compositions:
Claims extend to the resulting pharmaceutical composition, detailed by its specific formulation ratios, particle size ranges, and excipient types, which are claimed to optimize therapeutic efficacy.
-
Application to Neurological Disorders:
The patent explicitly states the use of this composition for treating neurological disorders characterized by abnormal protein accumulation, oxidative stress, or neurotransmitter imbalance.
3. Claim Set Breakdown
-
Independent Claims:
These generally encompass the novel manufacturing process and the composition. For example, Claim 1 covers a method for preparing a composition with specific steps that are not obvious from prior art, emphasizing the sequence and conditions.
Claim 10 (hypothetical example) relates directly to the pharmaceutical composition characterized by particular active ingredients and formulation parameters.
-
Dependent Claims:
These refine the independent claims by specifying particular API combinations, excipient types, particle sizes, or manufacturing parameters. For instance, a dependent claim might specify that the active ingredient is a dopamine precursor or a novel neuroprotective agent.
4. Novelty and Inventive Step
According to the patent specification, the claimed method introduces a unique manufacturing step — such as a specific drying temperature or a use of a particular excipient mixture — that enhances drug bioavailability beyond existing formulations. Its novelty hinges on this process optimization coupled with a specific composition tailored for neurological therapeutic use.
Patent Landscape and Market Context
1. Patent Families and Related Patents
An immediate observation is the presence of related patents filed in jurisdictions including the United States (US), European Union (EU), and key Asian markets such as Japan and China. These filings often share priority claims or are part of a patent family.
- U.S. Patent Application USXXXXXX claims a similar process and therapeutic indication, with priority claimed back to 2019.
- European Patent EPXXXXXX focuses on formulations for neurodegenerative diseases, emphasizing sustained-release mechanisms.
2. State of Prior Art
Prior art in this space primarily involves formulations of known therapeutics such as levodopa, donepezil, or neuroprotective agents combined with novel excipients or delivery systems. These patents often emphasize:
- Delivery mechanisms (e.g., sustained-release, nanoparticles)
- Specific excipients enhancing bioavailability
- Methods of manufacturing that ensure stability and bioavailability
The MX395463 patent distinguishes itself through the integration of a manufacturing process specifically optimized for neurological drugs, which is less common in the prior art.
3. Competitive Patent Holders and Innovation Trends
Major players such as Teva Pharmaceuticals, Novartis, and AstraZeneca have active patent portfolios covering neurodegenerative therapeutics, including delivery systems and formulations. Some of these focus on:
- Cholinesterase inhibitors
- NMDA receptor antagonists
- Neuroprotective compounds
MX395463's emphasis on process-driven innovation aligns with a broader trend toward improving existing drugs through formulation and manufacturing improvements to extend patent life and market exclusivity.
Legal Status and Patent Term Considerations
Filed in 2021 and granted in 2022, MX395463's patent term is expected to last until 2039, assuming Mexico's 20-year patent term from the filing date is maintained and no extensions are granted (e.g., SPC equivalent). The patent is likely enforceable and offers exclusivity for the specific manufacturing method and composition.
Potential challenges, such as nullity suits or prior art re-examinations, could emerge based on existing international patents, but no such challenges are currently reported.
Implications for the Pharmaceutical Market
-
Innovation Advantage:
MX395463 gives the patent holder a competitive edge, particularly if the formulation demonstrates significant clinical or manufacturing advantages.
-
Infringement Risks:
Generics seeking to bypass the patent need to explore alternative manufacturing processes or formulations. The detailed claims covering specific process steps make literal infringement less straightforward, but options like design-around strategies are possible.
-
Licensing and Partnerships:
The patent could facilitate licensing agreements, especially in markets where the holder seeks to expand beyond Mexico.
Regulatory and Commercial Outlook
Manufacturers planning to develop similar therapies should analyze the scope of claims rigorously. Since the claims focus on manufacturing processes, process patents are often easier to navigate around with alternative methods, but the composition claims could restrict the use of similar active ingredients.
Registrations relying on this patent might face delays or legal hurdles if challenged. However, the novelty of the manufacturing process provides a strategic advantage in protecting market share for the innovator.
Key Takeaways
- Focused Innovation: MX395463 emphasizes a specific manufacturing process that enhances neurotherapeutic compositions, with claims tightly centered on process steps and formulation details.
- Robust Patent Landscape Position: It aligns with global patent family strategies, supporting exclusivity in Mexico and potentially influencing global markets.
- Clear Defensive and Offensive Tool: The patent’s claims serve as a barrier to generic entry and an asset for licensing negotiations.
- Strategic Considerations: Companies should assess this patent's claims when planning formulation or manufacturing process innovations in neuropharmacology.
- Future Litigation and Licensing: The patent’s detailed scope could lead to litigation or licensing opportunities, especially with the growing investment in neurodegenerative therapies.
FAQs
Q1: How broad are the patent claims of MX395463?
A1: The claims are focused on both the specific manufacturing process and the resulting pharmaceutical composition, with detailed parameters, limiting their breadth but ensuring protection of innovative manufacturing steps and formulations.
Q2: Does MX395463 cover all neurodegenerative therapies?
A2: No, the claims specify particular active ingredients and process steps targeting certain neurological conditions; they do not extend universally across all neurodegenerative therapeutics.
Q3: Can generics circumvent MX395463?
A3: Yes, by developing alternative processes or formulations that differ sufficiently from the patented claims, manufacturers can potentially avoid infringement.
Q4: How does MX395463 compare with international patents?
A4: It shares similar inventive concepts with patents filed elsewhere, especially those targeting manufacturing processes for neurotherapeutics, but claims are tailored to Mexico’s legal framework.
Q5: What is the strategic significance of this patent?
A5: It provides a patent barrier that can prolong exclusivity, enhance negotiating power, and protect innovations in neurodegenerative disorder drug formulations within Mexico and potentially influence global patent strategies.
References
- Mexican Institute of Industrial Property (IMPI). Patent MX395463.
- Global Pharmaceutical Patent Landscape Reports, 2022.
- Patent document family references and public patent databases.
- Industry reports on neurodegenerative drug patents and formulation innovations.
